Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 10/20 | 0.64 |
| ▸ | IMPDH1 | P20839 | 3/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14518597 | 0.88 | IMPDH2 (0.65) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL15741823 | 0.86 | IMPDH2 (0.63) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL5531405 | 0.81 | AAK1 (0.75) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL4886184 | 0.79 | IMPDH2 (0.47) | IMPDH2IMPDH1AAK1MKNK1MKNK2 | |
| SCHEMBL6180479 | 0.79 | AAK1 (0.65) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1616817 | 0.79 | AAK1 (0.61) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL30298739 | 0.79 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6639753 | 0.79 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL1353846 | 0.79 | IMPDH2 (1.00) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6170243 | 0.78 | IMPDH2 (0.73) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2003087071-A1 | SULFONAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | IMPDH2 614/4885IMPDH1 527/4885AAK1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.